BELLUS HEALTH INCORPORATED (OTCMKTS:BLUSF) Sellers Increased By 107.14% Their Shorts

May 19, 2017 - By Darrin Black

The stock of BELLUS HEALTH INCORPORATED (OTCMKTS:BLUSF) registered an increase of 107.14% in short interest. BLUSF’s total short interest was 2,900 shares in May as published by FINRA. Its up 107.14% from 1,400 shares, reported previously. With 5,200 shares average volume, it will take short sellers 1 days to cover their BLUSF’s short positions. About 20,000 shares traded or 149.56% up from the average. BELLUS Health Inc (OTCMKTS:BLUSF) has risen 6.00% since April 19, 2017 and is uptrending. It has by 0.00% the S&P500.

BELLUS Health Inc. is a drug development firm focused on rare diseases. The company has market cap of $16.45 million. The business activities of the Company are development of the Company’s core technology platform, amyloid inhibitors, which focus on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils, which are the underlying causes of certain diseases. It currently has negative earnings. The Firm operates in the business segment of development of drugs for health solutions.

More notable recent BELLUS Health Inc (OTCMKTS:BLUSF) news were published by: which released: “Bellus Health Plummets After Protein-Fighting Drug Fails Test” on June 20, 2016, also with their article: “BRIEF-Bellus Health and the NEOMED Institute announce agreement for …” published on February 28, 2017, published: “BELLUS Health Announces Grant of New US Patent Covering Lead Compound for …” on April 24, 2017. More interesting news about BELLUS Health Inc (OTCMKTS:BLUSF) were released by: and their article: “BELLUS Health: Results From KIACTA Phase 3 Clinical Trial Expected In Mid-2016” published on November 18, 2015 as well as‘s news article titled: “Bellus Health Developing Shigamab For The Treatment Of STEC-HUS” with publication date: October 07, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.